68 results on '"Bueno, Á."'
Search Results
2. ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy
3. NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLL-r B-ALL by regulating NR3C1 expression
4. CD34+CD19−CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies
5. Discovery of a CD10-negative B-progenitor in human fetal life identifies unique ontogeny-related developmental programs
6. A human genome editing–based MLL::AF4 ALL model recapitulates key cellular and molecular leukemogenic features
7. Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia
8. HOXA9 promotes hematopoietic commitment of human embryonic stem cells
9. A Phase 1 First-in-Human Study of Abbv-383, a BCMA × CD3 Bispecific T-Cell-Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma
10. Clinical Genomic Analyses Demonstrate t(11;14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax
11. Highly Parallel Discovery of Synthetic Knockin Sequences for Enhanced Cancer Immunotherapies
12. CD84: A Novel Target for CAR T-Cell Therapy for Acute Myeloid Leukemia
13. FLT3 activation cooperates with MLL-AF4 fusion protein to abrogate the hematopoietic specification of human ESCs
14. Combinatorial effects of microRNAs to suppress the Myc oncogenic pathway
15. Enforced expression of MLL-AF4 fusion in cord blood CD34+ cells enhances the hematopoietic repopulating cell function and clonogenic potential but is not sufficient to initiate leukemia
16. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens
17. Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia
18. Natural history and cell of origin of TC F3-ZN F384 and PTPN11 mutations in monozygotic twins with concordant BCP-ALL
19. A Closer Look at Changes in Hemoglobin Levels in Patients with Non-Transfusion Dependent β-Thalassemia Treated with Luspatercept: Post Hoc Analysis of the Phase 2 BEYOND Trial
20. Combined Inhibition of MCL1 By AZD5991 and BCL2/Bclxl By AZD4320 As Promising Strategies to Overcome Acute Leukemia Tumor Burden and Niche Chemoresistance
21. HCK Inhibition Displays Antineoplastic Activity on Acute Leukemia and Promotes Immune Regulation of the Bone Marrow Tumor Microenvironment
22. Dose Escalation and Expansion of Abbv-383 in Combination with Anti-Cancer Regimens in Relapsed or Refractory Multiple Myeloma
23. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia
24. Design and in Vitro Evaluation of a CAR-T Prototype (ARI-0003) Targeting CD123 for Acute Myeloid Leukemia
25. Myelodysplastic Syndromes: Have You Seen Your Patient Beyond His Hemoglobin?
26. Burden of Sickle Cell Disease: A Brazilian Societal Perspective Analysis
27. Assessment of Minimal Residual Disease By Next-Generation Sequencing and Fluorodeoxyglucose-Positron Emission Tomography in Patients with Relapsed/Refractory Multiple Myeloma Treated with Venetoclax in Combination with Carfilzomib and Dexamethasone
28. Pediatric Acute Promyelocytic Leukemia in Brazil: Epidemiology, Molecular Features, and Importance of GST-Theta 1 in Chemotherapy Response and Outcome
29. Analysis of the Eligibility of Patients with Sickle Cell Disease for Palliative Care
30. A Novel Chemical Compound Inhibiting Hematopoietic Cell Kinase (iHCK) Has a Synergic Effect with Azacytidine (Aza) or Cytarabine (Ara-C) for Acute Myeloid Leukemia Treatment
31. Induced Transdifferentiation of Leukemia B-Cells to Macrophages Involves Reconfiguration of the DNA Methylome
32. Bone Marrow Mesenchymal Stromal Cells and Inflammation Contribute to ETV6-RUNX1+ Preleukemic Cells Persistence and DNA Damaging
33. The role of RUNX1 isoforms in hematopoietic commitment of human pluripotent stem cells
34. Prediction of Extended Red Blood Cell Phenotype from Exome Next Generation Sequencing Data
35. Allogeneic Hematopoietic Stem Cell Transplant in Advanced Multiple Myeloma: Experience from a Single Center
36. High Cardiac Output By Microfistulas: A New Pulmonary Hypertension Mechanism in Patients with Myelofibrosis and the Impact of the Treatment with Ruxolitinib
37. Cell-Cell Communication Between Multiple Myeloma (MM) Cells and Cord Blood Derived NK Cells (CB-NK) Regulates Both Tumor Cell Death and Tumor Cell Survival
38. Flow Cytometric Detection of Liposomes in the CSF of Patients with NHL/ALL, Treated with Intrathecal Liposomal Cytarabine: Synonymous of Toxicity?
39. Paroxysmal Nocturnal Hemoglobinuria and Magnetic Resonance Imaging
40. Paroxysmal Nocturnal Hemoglobinuria and Cancer: High Incidence Of Cancer In a Large Series Of PNH Patients In a Single Center
41. ABCB1 Haplotypes Are Associated With Lower P-Gp Activity and Major Molecular Response But Do Not Affect Imatinib Plasma Levels In Chronic Myeloid Leukemia Patients
42. Prognostic Impact of the Levels of Expression of Cell Surface Proteins Commonly Expressed by Blasts and Hematopoietic Precursor Cells in De Novo AML Patients: A Report From the Spanish Cetlam Study Group
43. Clofarabine-Based Chemotherapy for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. the Spanish Experience
44. ABCG2 and SLC22A1 Expression Are Associated with Imatinib Response in Chronic Myeloid Leukemia
45. Polymorphisms in Antitrombin (SERPINC1) and Tissue Factor Pathway Inhibitor (TFPI) Genes Are Associated with Recurrent Pregnancy Loss
46. Impact of Cytogenetics and New Molecular Markers On the Achievement of Complete Remission in Patients with Primary Acute Myeloid Leukemia. On Behalf of CETLAM Cooperative Group. Spain.
47. Five Pro-Inflammatory Molecules Polymorphisms Analysis in Ischemic Cerebrovascular Disease (ICD).
48. Global DNA Methylation Status of CD4+ T-Cell Population in Mielodysplastic Syndromes.
49. A Phase I/II, National, Multicenter, Open Label Study of Bortezomib (Velcade) and Fludarabine, Cytarabine and Idarubicin (Flag-Ida) (V-Flag-Ida) in Pts with Relapsed and/or Refractory Acute Myeloblastic Leukemia (AML).
50. IgM Multiple Myeloma: A Rare Subtype Highly Sensitive to Lenalidomide
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.